Why carry out this study?

Chimeric antigen receptor (CAR) T cell therapies have changed the treatment paradigm for patients with relapsed or refractory large B cell lymphoma (R/R LBCL).

There are three anti-CD19 CAR T cell therapies approved for R/R LBCL by the US Food and Drug Administration, but the relative cost-effectiveness of these therapies, accounting for site of care (i.e., inpatient/outpatient infusion), has not yet been well evaluated.

To address this knowledge gap, we constructed a payer perspective model to compare lifetime costs/benefits for CAR T cell-treated (axicabtagene ciloleucel [axi-cel], lisocabtagene maraleucel [liso-cel], tisagenlecleucel [tisa-cel]) patients with R/R LBCL in the USA.

What has been learned from this study?

For patients with R/R LBCL, axi-cel confers a greater survival benefit than other approved CAR T therapies and is also cost-effective compared to those therapies (i.e., tisa-cel and liso-cel).

Site of care does not impact the cost-effectiveness of CAR T cell therapy.